Search

The FDA first approved the drug in December 2021, and it is the only biologic approved for severe asthma with no phenotype or biomarker limitation within the approved label. Amgen and AstraZeneca The FDA has approved Amgen and AstraZeneca's tezepelumabekko (Tezspire) pen for individuals 12 years and older with severe asthma. It targets and blocks thymic stromal lymphopoietin, an epithelial cytokine on top of multiple inflammatory cascades, and triggers an overreactive immune response to allergic, eosinophilic, and other types of airway inflammations associated with severe asthma. [Extracted from the article]